Cannabidiol is under clinical development by Zynerba Pharmaceuticals and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Cannabidiol’s likelihood of approval (LoA) and phase transition for DiGeorge Syndrome took place on 17 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Cannabidiol Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Cannabidiol overview

Cannabidiol (ZYN-002) is under development for the treatment of neuropsychiatric disorders including developmental epileptic encephalopathy in children and adolescents, Fragile X syndrome in children and adolescents, adult refractory focal seizures, pediatric autism spectrum disorder (ASD) (pervasive developmental disorder) and 22q11.2 deletion syndrome. It is applied transdermally as a gel. The drug candidate targets cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors and also fatty acid amide hydrolase. It was also under development for the treatment of rheumatoid arthritis and knee pain due to osteoarthritis. It was under development for drug and alcohol addiction.

Zynerba Pharmaceuticals overview

Zynerba Pharmaceuticals, formerly AllTranz, is a developer of next-generation synthetic cannabinoid therapeutics. The company produce transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company provides pipeline product candidates includes ZYN002. Its ZYN002 is a synthetic CBD, a non- cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery. Zynerba Pharmaceuticals’s ZYN002 is administered as a transdermal gel to children and adolescents with autism spectrum disorder. The company’s pipeline candidates target various indications which include refractory epileptic focal, fragile x syndrome, developmental and epileptic encephalopathies and autism spectrum disorder. Zynerba Pharmaceuticals is headquartered in Devon, Pennsylvania, the US.

Quick View Cannabidiol LOA Data

Report Segments
  • Innovator
Drug Name
  • Cannabidiol
Administration Pathway
  • Transdermal
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
  • Immunology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.